Answers are grounded in this paper and cite their sources.
Pulmonary hypertension is a heterogeneous, progressive condition affecting pulmonary vasculature. Epidemiologic studies have highlighted underdiagnosis and persistent disparities in access to expert care, treatments, and outcomes. Biomarkers and imaging‑based phenotyping are enhancing early detection, while emerging technologies for monitoring and novel treatment targets show promise for a new horizon in individualized management of pulmonary hypertension. This review aims to summarize the epidemiology, pathogenesis, definitions, treatment, and future directions of pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Diaz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: